Future Perspectives in Renal Cell Carcinoma (RCC)

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.